# Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

> **NCT04994210** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Safety and Efficacy

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT04994210
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-04
- **Primary completion:** 2023-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04994210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04994210, "Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04994210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*